Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Pharvaris N.V. (NASDAQ:PHVS) have received a consensus recommendation of “Moderate Buy” from the fourteen research firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have given a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $42.7273.

A number of research firms have weighed in on PHVS. Citigroup reiterated a “buy” rating on shares of Pharvaris in a research note on Wednesday, April 15th. Royal Bank Of Canada lowered their target price on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research note on Monday, April 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a report on Tuesday, April 21st. Wedbush lifted their price objective on shares of Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a report on Tuesday, April 7th. Finally, Wall Street Zen cut shares of Pharvaris from a “sell” rating to a “strong sell” rating in a research report on Monday, April 13th.

Pharvaris Price Performance

Shares of NASDAQ:PHVS opened at $30.11 on Friday. The firm has a market capitalization of $1.97 billion, a PE ratio of -8.93 and a beta of -2.34. The business has a 50 day simple moving average of $27.71 and a two-hundred day simple moving average of $26.21. Pharvaris has a 1 year low of $14.59 and a 1 year high of $31.14.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings results on Friday, April 3rd. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.15). Equities research analysts expect that Pharvaris will post -3.19 EPS for the current fiscal year.

Insider Activity

In related news, insider Peng Lu sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $30.24, for a total value of $453,600.00. Following the completion of the sale, the insider owned 66,083 shares in the company, valued at approximately $1,998,349.92. The trade was a 18.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Johannes Gerardus Chri Schikan sold 29,070 shares of the stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $30.32, for a total value of $881,402.40. Following the completion of the transaction, the director directly owned 355,167 shares in the company, valued at approximately $10,768,663.44. This trade represents a 7.57% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 150,659 shares of company stock valued at $4,489,587. Corporate insiders own 11.84% of the company’s stock.

Institutional Trading of Pharvaris

Several institutional investors and hedge funds have recently made changes to their positions in PHVS. GF Fund Management CO. LTD. purchased a new stake in Pharvaris in the fourth quarter worth about $35,000. JPMorgan Chase & Co. raised its holdings in shares of Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in shares of Pharvaris in the 3rd quarter valued at about $75,000. Barclays PLC purchased a new stake in shares of Pharvaris in the 4th quarter worth approximately $77,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Pharvaris in the 4th quarter worth approximately $86,000.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.